A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas
| Autor: | William Pearse, Jane N. Winter, Sonali M. Smith, Irene Helenowski, Leo I. Gordon, Amir Behdad, Jason B. Kaplan, Andreas K. Klein, Shuo Ma, Reem Karmali, Adam M. Petrich, Andrew M. Evens, Barbara Pro, Borko Jovanovic |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
medicine.medical_specialty Herpesvirus 4 Human Immunoconjugates Lymphoma medicine.medical_treatment Lymphoproliferative disorders Ki-1 Antigen Neutropenia Gastroenterology Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Brentuximab vedotin Brentuximab Vedotin Immunosuppression Therapy Chemotherapy business.industry Immunosuppression Hematology Immunotherapy medicine.disease Lymphoproliferative Disorders Regimen Oncology Rituximab business medicine.drug |
| Zdroj: | Leukemialymphoma. 62(14) |
| ISSN: | 1029-2403 |
| Popis: | Treatment strategies for post-transplant lymphoproliferative disorders (PTLD) consist of response-adapted risk-stratified methods using immunosuppression reduction, immunotherapy, and chemotherapy. We investigated the efficacy of Brentuximab vedotin given concurrently with Rituximab (BV + R) once weekly for four weeks, followed by optional consolidation, and up to one year of maintenance. Among 20 assessable patients, BV + R therapy resulted in an overall response rate of 75% (95% CI 51 to 91, p = 0.044) with 60% achieving a complete response. Median time to best response was 28 days. Two-year progression-free survival and overall survival rates were 75 and 90%, respectively. Most common severe grade 3/4 treatment-related toxicities included neutropenia (40%), hypertension (30%), infection (25%), and peripheral neuropathy (15%). BV + R is a novel and effective therapeutic strategy that achieved rapid and durable remissions in previously untreated PTLD patients; however, this treatment platform requires further modification due to the high rates of treatment-related toxicity.Key pointsBrentuximab vedotin + Rituximab showed ORR and CR rates of 75 and 60% in patients with immunosuppression-associated lymphoid malignanciesHigh rates of treatment delay were attributed to treatment-related toxicity; further dosing optimization of this regimen is required. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|